布鲁辛A通过向多发性骨髓瘤中USP13/PARP1信号通路来抑制细胞增殖
Mengjie Guo1,2, Han Meng2, Yi Sun2
1Nanjing Hospital of Chinese Medicine Affiliated With Nanjing University of Chinese Medicine, Nanjing, China.
Basic & clinical pharmacology & toxicology
|March 28, 2025
概括
布鲁赛因A (BA) 通过向USP13/PARP1通路,显示出治疗多发性骨髓瘤 (MM) 的前景. 这种新的策略抑制了DNA损伤的修复,为这种无法治愈的癌症提供了潜在的新疗法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 多发性骨髓瘤 (MM) 是一种无法治愈的血液性恶性瘤,需要新的治疗方法.
- 布鲁素A (BA) 是一种天然化合物,具有抗癌特性,但其对MM的机制尚不清楚.
研究的目的:
- 阐明Bruceine A (BA) 在对抗多发性骨髓瘤 (MM) 的药理机制.
- 确定和验证USP13作为MM治疗的治疗标.
主要方法:
- 利用患者数据将USP13表达与MM预后相关联.
- 使用质谱,共免疫沉和无处不在测试来识别USP13目标.
- 使用MM细胞系,患者衍生的异种移植和小鼠模型验证了BA的疗效.
主要成果:
- 在MM患者中,USP13表达升高,与预后不佳有关,促进MM细胞增殖.
- 在MM细胞中,USP13可分离并稳定PARP1,增强DNA损伤修复 (DDR).
- 在临床前模型中,BA治疗抑制了USP13/PARP1信号传输,并破坏了DDR,从而减少了MM的进展.
结论:
- 通过稳定PARP1和促进DDR,USP13是MM进展的关键驱动因素.
- 用Bruceine A针对USP13/PARP1轴是一种有前途的治疗策略,用于多发性骨髓瘤.
相关概念视频
Negative Regulator Molecules
32.1K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
32.1K
Drugs that Stabilize Microtubules
2.2K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
The Intrinsic Apoptotic Pathway
6.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K


